List of Excipients in Branded Drug CABOMETYX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Exelixis Inc	CABOMETYX	cabozantinib	42388-023	ANHYDROUS LACTOSE	2032-03-26
Exelixis Inc	CABOMETYX	cabozantinib	42388-023	CELLULOSE, MICROCRYSTALLINE	2032-03-26
Exelixis Inc	CABOMETYX	cabozantinib	42388-023	CROSCARMELLOSE SODIUM	2032-03-26
Exelixis Inc	CABOMETYX	cabozantinib	42388-023	FERRIC OXIDE YELLOW	2032-03-26
Exelixis Inc	CABOMETYX	cabozantinib	42388-023	HYDROXYPROPYL CELLULOSE	2032-03-26

CABOMETYX Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

CABOMETYX is an oral cabozantinib tablet marketed by Exelixis for advanced renal cell carcinoma, hepatocellular carcinoma previously treated with sorafenib, and combination treatment with nivolumab for advanced RCC. Its excipient strategy is conventional, low-cost, and difficult to differentiate through ordinary tablet composition alone. The strongest commercial opportunities are generic supply, formulation engineering, pediatric or dysphagia-friendly presentations, regional manufacturing, and excipient supply-chain optimization.

The main business constraint is that an excipient redesign does not automatically avoid cabozantinib composition, method-of-use, or formulation patent claims. A successful commercial program must combine bioequivalence, pharmaceutical equivalence, regulatory exclusivity analysis, and a patent clearance strategy.

What is the CABOMETYX formulation and which excipients does it contain?

CABOMETYX is supplied as film-coated tablets containing cabozantinib S-malate, equivalent to 20 mg, 40 mg, or 60 mg of cabozantinib. The tablets are administered orally and should not be crushed, chewed, or split because the product is designed for intact tablet administration.[1]

Public FDA labeling identifies the core tablet excipients as:

Formulation component	Reported function
Microcrystalline cellulose	Diluent and compression aid
Croscarmellose sodium	Superdisintegrant
Sodium starch glycolate	Superdisintegrant
Colloidal silicon dioxide	Glidant and flow aid
Stearic acid	Lubricant
Hypromellose or related film-forming polymers	Film coating
Titanium dioxide and iron oxide pigments	Opacity and color
Other coating components	Film flexibility, processing, and surface finish

The exact regulatory filing should control for development work because inactive-ingredient listings can differ by strength, manufacturing site, market, or later label revision. FDA labeling and DailyMed remain the controlling public sources for the marketed product composition.[1,2]

The formulation is consistent with a conventional immediate-release, direct-compression or highly compactable tablet platform. It does not depend on a complex lipid system, osmotic delivery system, enteric coating, microsphere, or long-acting depot technology.

Why is the CABOMETYX excipient strategy commercially important?

The excipients influence four commercial variables: manufacturing cost, dissolution performance, tablet robustness, and regulatory comparability.

Cabozantinib has a narrow commercial tolerance for formulation variability because the marketed doses are relatively potent and treatment is associated with clinically important adverse reactions, including diarrhea, palmar-plantar erythrodysesthesia, fatigue, hypertension, and hepatotoxicity.[1] A generic formulation must provide consistent exposure without creating faster dissolution, altered food sensitivity, or greater dose dumping risk.

The core formulation strategy has several advantages:

1. It uses widely available pharmaceutical excipients.
2. It avoids dependence on proprietary delivery technology.
3. It supports multiple tablet strengths.
4. It permits supplier substitution, subject to qualification.
5. It can support conventional generic development under an abbreviated new drug application.

The principal weakness is limited product differentiation. A competitor using the same functional classes of excipients may obtain a technically equivalent formulation without offering a clinically distinct product.

What formulation attributes must a CABOMETYX generic match?

A CABOMETYX generic must address more than the nominal active ingredient and strength. FDA review will focus on pharmaceutical equivalence, bioequivalence, quality, and manufacturing controls.

Dose proportionality and strength design

The 20 mg, 40 mg, and 60 mg presentations create a three-strength development program. A manufacturer can use common granulation or compression parameters, but each strength must meet content uniformity, dissolution, assay, degradation, hardness, friability, and stability requirements.

A proportional formulation can lower development and validation costs. However, dose proportionality should not be assumed. The active-to-excipient ratio changes across strengths, and low-dose tablets can be more sensitive to blend uniformity and segregation.

Dissolution and disintegration

Croscarmellose sodium and sodium starch glycolate provide rapid tablet breakup. Their relative concentration, particle size, swelling behavior, and distribution can materially affect dissolution.

Potential generic development variables include:

• Replacing one superdisintegrant with another.
• Using crospovidone to improve disintegration or reduce variability.
• Changing the lubricant level to reduce hydrophobic dissolution effects.
• Adjusting microcrystalline cellulose grade for compactability.
• Replacing colloidal silicon dioxide with another approved glidant.
• Modifying coating weight without changing release behavior.

These changes can reduce cost or improve manufacturing robustness, but they increase the need for comparative dissolution and stability work.

Tablet handling and coating

The film coat supports identification, moisture protection, and mechanical durability. A generic manufacturer may redesign the coating color, polymer blend, or pigment system, subject to regulatory requirements and trade-dress restrictions.

The product should remain easy to identify by strength. A robust color-coding system reduces dispensing errors, particularly because treatment may involve dose reductions from 60 mg to 40 mg or 20 mg.

What excipient substitutions create the strongest generic opportunities?

The most commercially attractive substitutions are those that preserve performance while reducing supply-chain exposure or manufacturing complexity.

Opportunity	Commercial rationale	Key development issue
Alternative microcrystalline cellulose grade	Dual sourcing and lower excipient cost	Tablet tensile strength and dissolution
Crospovidone substitution	Potentially simpler disintegration profile	Comparative dissolution and compactability
Reduced lubricant load	Improved wetting and dissolution	Ejection force and tablet defects
Alternative film-coat system	Lower coating time or regional sourcing	Color, stability, and product identification
Direct-compression platform	Lower processing cost	Blend uniformity and segregation
Low-moisture manufacturing	Better stability control	Electrostatic behavior and flow
Common formulation across strengths	Lower validation and inventory burden	Dose uniformity at the 20 mg strength

The strongest initial strategy is usually a conservative formulation using the same functional excipient classes, followed by targeted optimization. A radical excipient redesign is less attractive unless it delivers a measurable benefit in dissolution, stability, manufacturability, or patient use.

What excipient-related patent risks affect CABOMETYX?

Excipient substitution can reduce exposure to formulation-specific claims, but it may not address broader patent barriers.

Patent risk can arise from four claim categories:

Cabozantinib composition claims

A composition-of-matter patent covering cabozantinib or its salt can block a generic regardless of excipient selection. A redesigned tablet does not avoid an active-ingredient patent.

Method-of-use patents

CABOMETYX is approved for multiple oncology uses, including RCC and HCC. A generic applicant may need to use a section viii statement to omit patented indications or may need to address listed method-of-use patents through a Paragraph IV certification.[3]

Formulation patents

A formulation patent may claim:

• A specific cabozantinib salt.
• A defined particle-size distribution.
• A particular dissolution profile.
• A tablet containing specified excipient ratios.
• A coating or stability system.
• A combination formulation with nivolumab-related treatment methods.

The commercial value of a formulation patent depends on claim scope. A claim limited to a narrow excipient ratio may be easier to design around than a claim covering a broad cabozantinib tablet composition.

Manufacturing patents

Manufacturing claims may cover crystallization, salt formation, particle engineering, granulation, drying, or tablet production. These claims can affect API sourcing even when the finished tablet uses nonidentical excipients.

The FDA Orange Book should be reviewed for current listed patents and exclusivity codes before a generic filing strategy is finalized.[3] Patent expiration dates can change because of patent-term adjustment, pediatric exclusivity, terminal disclaimers, or litigation outcomes.

When does CABOMETYX lose exclusivity and when could generic entry occur?

CABOMETYX has several layers of regulatory and patent protection. FDA approved cabozantinib products in different indications at different times, creating a staggered exclusivity profile.[1,4]

Protection category	Relevance to CABOMETYX
New chemical entity exclusivity	Applies to the original FDA approval of cabozantinib products, subject to statutory timing
Orphan-drug exclusivity	May affect specific indications if the approved use received orphan designation
Patent protection	Can cover the active ingredient, salt, formulation, methods of use, and manufacturing
Pediatric exclusivity	Can add six months to qualifying listed protections
Regulatory exclusivity for later indications	Can delay approval of certain uses by an ANDA or other abbreviated pathway

A generic applicant can file an ANDA before patent expiry and certify against listed patents. A Paragraph IV certification can trigger litigation under the Hatch-Waxman framework. The first eligible Paragraph IV applicant may obtain 180-day exclusivity, although that benefit depends on statutory requirements and the applicant's commercial conduct.[5]

The practical entry date depends on the earliest enforceable patent, the claims asserted in litigation, settlement terms, and whether the generic launches at risk. Patent expiry should therefore be modeled as a range of scenarios rather than a single date.

Which companies are likely to challenge or compete with CABOMETYX?

CABOMETYX generic competition is most likely to come from established oncology-generic companies with:

• Experience in potent oral oncology products.
• Controlled-substance or high-containment manufacturing capability where required.
• Internal bioequivalence infrastructure.
• Access to cabozantinib API or a qualified API supplier.
• A willingness to litigate Paragraph IV cases.
• Distribution relationships with specialty pharmacies and oncology clinics.

Potential competitive groups include large generic manufacturers, specialty oncology suppliers, and regional companies pursuing limited-launch products. The number of commercial entrants will depend on the litigation outcome and the attractiveness of the market at patent expiry.

A first entrant may capture substantial value through 180-day exclusivity. Later entrants may compete primarily on wholesaler discounts, pharmacy access, supply reliability, and contract pricing.

What commercial opportunities exist for CABOMETYX excipients?

Generic tablet manufacturing

The largest opportunity is supply of an equivalent immediate-release tablet. The excipient bill of materials is unlikely to create a high price premium, so the economic model depends on manufacturing scale, API cost, yield, and market entry timing.

Dual-source excipient platforms

A manufacturer can create value by qualifying two grades or suppliers for each critical excipient. This reduces production interruptions caused by shortages, regional regulatory restrictions, or changes in excipient availability.

The highest-priority materials are the superdisintegrants, microcrystalline cellulose, lubricant, and coating system. Changes to these materials can affect dissolution and therefore require formal change control.

Alternative dosage forms

An oral suspension, dispersible tablet, or smaller swallowable tablet could address patients with dysphagia, treatment-related weakness, or difficulty swallowing conventional tablets. These products would face significant development and regulatory barriers because the approved product is an intact tablet and cabozantinib exposure is clinically sensitive.

A liquid product could require a new drug application or a 505(b)(2) pathway rather than a straightforward ANDA, depending on the formulation, labeling, and reliance strategy.[6] It would also create stability, preservative, container-closure, dosing-device, and occupational-exposure issues.

Pediatric formulation

Cabozantinib is used primarily in oncology populations, but pediatric oncology indications or clinical development can create demand for lower-dose and flexible-dose presentations. A pediatric formulation could use multiparticulates, mini-tablets, or a reconstituted liquid.

The commercial case depends on pediatric market size, exclusivity rights, clinical demand, and whether an innovator or generic company controls the relevant indication.

Regional excipient and contract manufacturing

Manufacturers in Europe, India, China, and other regulated markets can compete by offering:

• Qualified alternate excipient sources.
• Lower-cost film coating.
• Small-batch oncology manufacturing.
• Regional packaging and serialization.
• Local regulatory support.
• High-containment or segregated production.

The main barrier is not excipient availability. It is consistent control of a potent oncology product across API, blending, compression, coating, packaging, and cleaning validation.

How strong is the CABOMETYX formulation patent estate?

The formulation patent estate should be assessed claim by claim. A broad claim covering a cabozantinib tablet with standard excipients may create a meaningful barrier. A narrow claim requiring a precise ratio, particle size, or dissolution range may be more vulnerable to design-around development.

A practical strength assessment should score:

Factor	Strong position	Weak position
Claim breadth	Covers multiple excipient classes and ratios	Limited to a narrow formulation
Written description	Supports broad commercial embodiments	Supports only one laboratory example
Enablement	Demonstrated across strengths and processes	Limited stability or scale-up data
Infringement proof	Product characteristics are readily measurable	Requires confidential process evidence
Design-around options	Few viable substitutions	Multiple conventional alternatives
Patent life	Extends beyond expected regulatory exclusivity	Near-term expiry
Litigation history	Claims survived validity challenges	Prior adverse claim construction or invalidity rulings

CABOMETYX's commercial barrier is likely to depend more heavily on active-ingredient and method-of-use patents than on ordinary excipient selection. A generic company should not treat a changed disintegrant or coating polymer as a complete freedom-to-operate solution.

What is the FDA regulatory status of CABOMETYX?

FDA approved CABOMETYX tablets in 2016 for advanced RCC in patients previously treated with antiangiogenic therapy. FDA later approved the product for previously treated HCC and for use with nivolumab in previously untreated advanced RCC.[1]

CABOMETYX is distinct from COMETRIQ, another cabozantinib product marketed in a different dosage form and approved for medullary thyroid cancer. The products contain the same active moiety but have different formulations, strengths, labeling, and regulatory histories.[4]

This distinction matters for commercial planning. A CABOMETYX tablet generic cannot assume that a COMETRIQ formulation, patent analysis, or clinical label can be used without separate regulatory review.

What litigation and settlement issues affect generic launch planning?

A Paragraph IV challenge could produce one of four outcomes:

1. The generic wins patent litigation and launches before the expected expiry date.
2. The patent holder prevails and delays entry.
3. The parties settle for a licensed entry date.
4. The generic launches at risk while litigation continues.

Settlement agreements can include delayed entry, authorized generic rights, supply arrangements, or restrictions tied to particular indications. The commercial value of an entry date depends on the number of competing ANDA filers and whether an authorized generic is launched during the first-filer period.

For an excipient-focused company, licensing can be attractive where it supplies a proprietary coating, disintegration system, or manufacturing process to an ANDA sponsor. The supplier's value increases if the technology improves bioequivalence probability or mitigates a listed formulation patent.

How does CABOMETYX compare with other oral oncology drugs?

CABOMETYX has a more conventional tablet platform than many modified-release or targeted-delivery oncology products. That reduces formulation complexity but also lowers the defensibility of excipient innovation.

Product characteristic	CABOMETYX	Complex oral oncology product
Dosage form	Film-coated immediate-release tablet	May use modified release or specialized delivery
Excipient complexity	Conventional	Often higher
Generic development	Technically feasible	May require complex characterization
Excipient differentiation	Limited	Can be commercially meaningful
Main patent risk	Active ingredient and use claims	Formulation and device claims may dominate
Supply-chain opportunity	Strong	Depends on specialized materials

The generic opportunity is therefore operational and timing-driven. It is less likely to depend on a high-value proprietary excipient platform.

Key Takeaways

• CABOMETYX uses a conventional film-coated tablet with common excipient classes.
• The main excipient opportunities are generic manufacture, alternate sourcing, coating optimization, and flexible-dose presentations.
• A superdisintegrant, lubricant, or coating substitution can improve cost and supply resilience but must preserve dissolution and bioequivalence.
• Excipient redesign does not necessarily avoid cabozantinib composition, method-of-use, manufacturing, or formulation patents.
• The FDA Orange Book and current patent litigation records control the timing analysis for Paragraph IV entry.
• A pediatric liquid, dispersible tablet, or smaller tablet could create differentiated commercial value, but these products may require a 505(b)(2) or new drug application strategy.
• The strongest near-term opportunity is a compliant, supply-secure generic tablet platform with three strengths and a conservative formulation design.

FAQs About CABOMETYX Excipients and Commercial Strategy

Can CABOMETYX tablets be reformulated with different excipients?

Yes. A generic manufacturer can use different inactive ingredients if the product meets FDA requirements for safety, quality, pharmaceutical equivalence, and bioequivalence. The change must also avoid infringement of enforceable formulation claims.

Is CABOMETYX an extended-release formulation?

No. CABOMETYX is labeled as an oral film-coated tablet rather than an extended-release dosage form. Its performance depends on immediate-release tablet disintegration, dissolution, absorption, and systemic exposure.[1]

Can a company market cabozantinib as a liquid formulation?

Potentially, but a liquid formulation would require separate development, stability, dosing, container-closure, and regulatory analysis. It may not qualify for the same ANDA pathway used for an equivalent tablet.

Which excipient is most important for CABOMETYX dissolution?

The superdisintegrant system is a major contributor because it controls tablet breakup. Lubricant concentration, microcrystalline cellulose grade, compression force, and coating characteristics can also affect dissolution.

Is COMETRIQ a substitute for CABOMETYX in generic development?

No. Although both products contain cabozantinib, they have different approved products, dosage forms, strengths, labels, and regulatory histories. A COMETRIQ strategy cannot be transferred automatically to CABOMETYX.

References

1. U.S. Food and Drug Administration. (2024). CABOMETYX (cabozantinib) tablets, prescribing information. Exelixis, Inc.

2. National Library of Medicine. (2024). DailyMed: CABOMETYX cabozantinib tablet, film coated. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). COMETRIQ (cabozantinib) capsules, prescribing information. Exelixis, Inc.

5. U.S. Government Publishing Office. (2024). 21 U.S.C. § 355: New drugs. United States Code.

6. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.